{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-022895","form_type":"8-K","ticker":"GOVX","cik":"0000832489","company_name":"GeoVax Labs, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.756764+00:00","generated_at":"2026-06-11T20:49:49.337828+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"GeoVax Q2 2023 net loss widens to $5.93M ($0.22/sh); cash at $17.8M","bullets":["Net loss for Q2 2023 was $5.93M ($0.22/sh) vs $2.24M ($0.18/sh) in Q2 2022.","R&D expenses jumped to $4.72M from $1.31M YoY, driven by clinical trial and manufacturing costs.","Cash and equivalents totaled $17.8M at June 30, 2023, down from $27.6M at Dec 31, 2022.","Initiated Phase 2 trial of GEO-CM04S1 in CLL patients; Gedeptin Phase 1/2 interim data showed no DLTs.","Expanded GEO-CM04S1 rights to include Mpox and smallpox; partnered with ABL for cGMP manufacturing."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-022895","json":"https://secwatch.observer/filing/0001437749-23-022895.json","markdown":"https://secwatch.observer/filing/0001437749-23-022895.md","text":"https://secwatch.observer/filing/0001437749-23-022895.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/832489/000143774923022895/0001437749-23-022895-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/832489/000143774923022895/govx20230809_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T20:49:49.337828+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"abee4908a8844e48b4fb4d03a4d772a7f8374e9f","claim":"GeoVax Labs, Inc. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/832489/000143774923022895/0001437749-23-022895-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}